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Novel somatic variants involved 
in biochemical activity of pure 
growth hormone‑secreting 
pituitary adenoma without GNAS 
variant
Cheol Ryong Ku1,7, Hyeonseob Lim2,7, Yang Jong Lee1,7, Sun Ho Kim3,4,7, Daham Kim1, 
Se Hoon Kim5, Mi Kyung Lee6, Duhee Bang 2* & Eun Jig Lee 1*
We aimed to identify somatic genetic alterations in pure growth hormone (GH)‑secreting pituitary 
adenomas without GNAS variants. Patients with GH‑secreting pituitary adenoma who underwent 
transsphenoidal adenomectomy at Severance Hospital, Yonsei University College of Medicine 
were recruited. Somatic genetic alterations were profiled by whole‑exome sequencing (WES) and 
targeted resequencing. WES was performed using DNA from nine GH‑secreting pituitary tumors 
and corresponding blood samples. Absence of GNAS variant was confirmed by Sanger sequencing. 
For targeted resequencing of 140 fixed tissues, 48 WES‑derived candidate genes and 7 GH‑secreting 
pituitary adenoma‑associated genes were included. Forty‑eight genes with 59 somatic variants were 
identified by WES. In targeted resequencing, variants in 26 recurrent genes, including MAST4, PRIM2, 
TNN, STARD9, DNAH11, DOCK4, GPR98, BCHE, DARS, CUBN, NGDN, PLXND1, UNC5B, and COL22A1, 
were identified, but variants in previously reported genes were not detected. BCHE, DARS, NGDN, and 
UNC5B variants were associated with increased GH‑secreting pituitary tumor biochemical activity, 
which was confirmed in vitro. Although recurrent point variants were rare, several somatic variants 
were identified in sporadic pure GH‑secreting pituitary adenomas. Several somatic variants may 
affect pathways involved in the tumorigenesis and biochemical activities of GH‑secreting pituitary 
adenomas.
Growth hormone (GH)-secreting pituitary adenoma is the most common cause of acromegaly, which is asso-
ciated with high mortality caused by cardiovascular disease, metabolic disorders, and  malignancies1–3. Many 
pituitary adenomas have a monoclonal origin, indicating that they are formed from the replication of a single 
cell that gained a growth advantage, possibly as a result of genetic or epigenetic modifications leading to proto-
oncogene activation or tumor suppressor gene  inactivation4,5. Despite extensive research, however, little is known 
about the genetic causes of pituitary adenomas. Although most pituitary adenomas are sporadic tumors, the only 
variants found in most cases of sporadic GH-secreting adenomas to date (approximately 35–40%) occur in the 
gene for the stimulatory G-protein α-subunit (GNAS)6–8.
Understanding the tumor pathology requires identifying and understanding the genetic alterations that drive 
tumorigenesis initiation and progression. The advancement of powerful computational methods, combined 
with next-generation sequencing technology, allows for the characterization of the somatic landscape through 
human tumors and variants important for diagnostic and therapeutic  purposes9,10. The somatic landscape has 
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been studied in several sporadic pituitary adenomas by exome  sequencing11–13. However, few variants, such as 
the USP8 variant in Cushing’s disease, have been identified by exome sequencing.
We performed somatic variant profiling based on whole-exome sequencing (WES) and targeted resequenc-
ing analysis in a large and well-characterized collection of 50 of 140 patients with acromegaly with pure GH-
expressing pituitary adenomas without GNAS variants (Fig. 1). We aimed to identify the somatic variants that 
may be associated with clinical differences in patients with GH-secreting pituitary adenoma.
Results
WES. WES was performed to identify novel genes related to pure GH-secreting pituitary adenoma. Based on 
our aims, nine patients not carrying a variant at codon 201 or codon 227 of GNAS were selected for the cohort 
(Supplementary Table S1). Tumor tissue and blood samples were sequenced, and the data were analyzed with 
bioinformatics software (Fig. 2a).
Although the Ti/Tv ratio observed (47/53 = 0.89; Fig. 2b) was lower than the commonly reported ratio of ~ 2, 
Sanger sequencing of several mutant loci agreed with the data (Supplementary Fig. S1).
A total of 48 genes with 59 variants were confirmed for profiling (Fig. 2c). Additionally, whole genomic 
regions of seven genes (HMGA2, FGFR4, PTTG1, RB1, GNAS, AIP, GPR101) associated with acromegaly were 
added to the profiling target (Supplementary Table S2).
Targeted resequencing. We performed targeted sequencing to validate variants in the targeted genes 
(Fig. 3a). Among the 140 genomic DNA samples prepared from formalin-fixed, paraffin-embedded (FFPE) tis-
















































Figure 1.  Schematic flow diagram of the current study. Genetic variants were investigated in three stages. 
In the first stage, “Target Discovery Stage,” blood and tissue samples of 30 patients were analyzed by Sanger 
sequencing, whole-exome sequencing (WES), and single nucleotide variant (SNV) validation resequencing, and 
genes with somatic variants were identified as target genes for profiling. In the second stage, “Target Profiling 
Stage,” target genes from 140 FFPE samples were analyzed by targeted resequencing, and relevant variants were 
selected for further validation. In the third stage, “In vitro Validation Stage,” selected variants were functionally 
examined by in vitro validation. Expression vectors containing variants were constructed and transfected into 
GH3 cell lines (drawn in Microsoft 365 Powerpoint; https:// www. micro soft. com/ ko- kr/ micro soft- 365).
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the validation cohort. The samples were captured and sequenced to obtain high-depth sequencing data, which 
were analyzed to profile variants.
Twenty-six genes carrying variants were identified (Fig. 3b, Supplementary Fig. S2). MAST4 was the most 
frequently mutated gene, found in 8% (4/50) of GNAS-negative patients. PRIM2, TNN, STARD9, DNAH11, 
DOCK4, and GPR98 were found in 6% (3/50) of the cohort, and BCHE, DARS, CUBN, NGDN, PLXND1, UNC5B, 
and COL22A1 were found in 4% (2/50) of the cohort. However, no variant was shared between any two samples, 



























































































Figure 2.  Somatic variant profiles of the discovery cohort. (a) Analysis pipeline used for whole-exome 
sequencing (WES) data (drawn in Microsoft 365 Powerpoint). (b) Relative ratio of transition and transversion 
variants (created in Microsoft 365 Excel; https:// www. micro soft. com/ ko- kr/ micro soft- 365). (c) Somatic variant 
profiles of the eight tissue-derived samples. Genes were sorted in descending order of frequency. The profile of 
the FFPE-derived sample was not plotted because of the low quality of the sequencing data. NGDN (p.S79C) 
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Statistical analysis of candidate variants. To investigate potential causal variants in the candidate 
genes found by WES and targeted resequencing, additional statistical analysis was performed. Variant-related 
Gene Ontology (GO) was analyzed using the Enrichr tool. The lists of genes found by WES and targeted rese-
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Figure 3.  Variant profiles of the validation cohort. (a) Analysis pipeline used for targeted resequencing data 
(drawn in Microsoft 365 Powerpoint). (b) Variant profiles of validation cohort. Genes were sorted in descending 
order of frequency (created in Microsoft 365 Excel). (c) Representative images of Sanger sequencing of DARS, 
BCHE, and NGDN. Left and right panels represent the genotype of the tissue and blood, respectively (created in 
Snap Gene Viewer; https:// www. snapg ene. com/ snapg ene- viewer/).
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:16530  | https://doi.org/10.1038/s41598-021-95829-3
www.nature.com/scientificreports/
quencing were queried, and five high-ranked terms were compared (Supplementary Tables S3 and S4). Amyloid-
beta binding (GO:0,001,540) terms in the molecular function category that are associated with GH-secreting 
pituitary  adenomas14 were commonly found in WES and targeted resequencing, and BCHE and CLSTN1 were 
related to the terms. Additionally, G-protein coupled receptor-related terms were observed in the WES results. 
G-protein coupled amine receptor activity (GO:0008227), G-protein coupled neurotransmitter receptor activ-
ity (GO:0099528), and G-protein coupled acetylcholine receptor activity (GO:0016907) terms were detected, 
with CHRM2 and OR6T1 related to the terms. Considering that CHRM3 is a paralog of CHRM215, we predicted 
that CHRM2 may be important. However, only a small number of genes was related to the GO terms, whereas 
enriched GO terms analyzed from previously reported genes (Supplementary Table S5) resulted from a much 
larger number of related genes (Supplementary Table S6). Therefore, we analyzed the relationship between the 
variants and clinical manifestations to investigate whether the variants were associated with a phenotype, such 
as GH secretion.
The clinical manifestations of 50 patients selected for targeted resequencing are presented in Table 1. There 
was no significant difference in tumor size, age, sex, or Ki67 index according to the genetic variants. However, 
some variants were associated with the biochemical activities of GH-secreting pituitary adenoma, such as BCHE, 
DARS, NGDN, and UNC5B variants (Table 1). Although significance could not be calculated because of the 
limited number of subjects, the patients presented exceptionally increased GH and IGF-1 levels before trans-
sphenoidal adenomectomy. Variants were validated by Sanger sequencing (Fig. 3c, Supplementary Fig. S3). The 
patients had no family history of pituitary adenomas or other neuroendocrine tumors.
Role of somatic variant in GH3 cells. The results from WES and targeted resequencing and clinical 
results from GH-secreting pituitary adenoma patients confirmed that variants in BCHE, DARS, NGDN, and 
UNC5B may be involved in GH secretion. Therefore, in vitro experiments using rat GH-secreting GH3 cells 
were performed to investigate the effect of those gene variants on GH secretion. We detected the expression 
of proteins responsible for GH secretion (Fig. 4a) using GH3 cells transfected with each mutant of the selected 
genes (BCHE, DARS, NGDN, and UNC5B) and incubated the cells for 48 h. Phosphorylation of mTOR increased 
with transfection of DARS p.T343I (25%, p = 0.019), NGDN p.S79C (59%, p = 0.034), and NGDN p.R100H (95%, 
p = 0.031) mutants, and that of CREB increased with transfection of BCHE p.W571C (25%, p = 0.017), UNC5B 
p.V245M (99%, p = 0.031), and UNC5B p.S471C (194%, p = 0.002) mutants (Fig. 4a).
As transfection of mutants in GH3 cells significantly affected the signaling pathway of GH synthesis and 
secretion, we analyzed the concentration of GH secreted into the cell-culture media by enzyme-linked immuno-
sorbent assay (ELISA). Among the several mutants, transfection of BCHE p.P320L (16%, p-value = 0.018), NGDN 
p.S79C (55%, p = 0.027), and NGDN p.R100H (50%, p = 0.047) mutants significantly increased GH secretion in 
Table 1.  Clinical characteristics of patients with somatic variants in growth hormone (GH)-secreting pituitary 
adenoma.
Total
NGDN BCHE DARS UNC5B
S79C R100H P320L W571C V120G T343I V245M S471C
Age (years old) 43 (24–72) 34 54 36 41 54 34 43 44
Sex
Male 13 (26%) 0 1 0 1 1 0 0 1
Female 37 (74%) 1 0 1 0 0 1 1 0
Hardy classification
I 12 (24%) 0 0 0 0 0 0 1 1
II 12 (24%) 0 0 0 0 0 0 0 0
III 12 (24%) 1 0 0 0 0 1 0 0
IV 14 (28%) 0 1 1 1 1 0 0 0
Immunohistochemical staining
Focal GH 1 (2%) 0 0 0 0 0 0 0 0
GH 45 (90%) 1 1 1 1 1 1 1 1
Weak GH 4 (8%) 0 0 0 0 0 0 0 0
Ki67 staining (%)
 < 1 24 (48%) 0 0 0 0 0 0 1 1
1–2 10 (20%) 0 0 1 0 0 0 0 0
2–3 7 (14%) 0 1 0 0 1 0 0 0
Not checked 9 (18%) 1 0 0 1 0 1 0 0
Preoperative OGTT 
Basal GH (ng/dL) 15.0 (2.2–229.0) 139.2 109 19.29 21.8 109 139.2 3 59.13
Nadir GH (ng/mL) 11.0 (2.1–118.9) 118.9 41.4 17.29 15.7 41.4 118.9 2.1 44.1
IGF-1 (μg/L) 660.6 (355.3–1282.6) 971.5 907.8 884.4 814 907.8 971.5 355.3 1282.6
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cell-culture media compared with the vector used as a negative control (Fig. 4c). The amount of GH secreted 
in the media was normalized to the optical density values obtained for the same samples from the MTS assay 
(Fig. 4c). Furthermore, the effects of each mutant on cell proliferation were analyzed by MTS assay under the 
same experimental conditions. Compared with negative control-transfected cells, transfection of BCHE p.P320L 
(6%, p = 0.001), BCHE p.W571C (10%, p = 0.001), NGDN p.S79C (10%, p = 0.012), and NGDN p.R100H (11%, 
p = 0.030) mutants slightly increased cell proliferation (Fig. 4b). Based on the ELISA and MTS assays, the variants 
in NGDN and BCHE may affect GH secretion and tumor growth in GH-secreting pituitary adenomas. Finally, 






























































































































































































Figure 4.  Biological role of somatic variants in GH3 cells. (a) Protein expression of genes responsible 
for growth hormone (GH) synthesis and secretion difference. Images of full-length blots are included in 
Supplementary Fig. S4 (created in Microsoft 365 Powerpoint, Excel). (b) GH secretion into the cell-culture 
media and (c) cell proliferation were also analyzed using transfected cells (created in Microsoft 365 Excel). 
All data are represented as the mean ± SE of triplicate experiments and representative of three independent 
experiments. Significant differences are denoted as *p < 0.05, **p < 0.01.
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Discussion
In this study, we identified novel somatic variants associated with pure GH-secreting pituitary adenoma from 
patients with neither GNAS variants nor a family history. The following are the major findings of our study: (a) 
48 genes with 59 somatic variants were identified among nine patients using WES; (b) targeted resequencing 
revealed variants in 26 recurrent genes, including in MAST4, PRIM2, TNN, STARD9, DNAH11, DOCK4, GPR98, 
BCHE, DARS, CUBN, NGDN, PLXND1, UNC5B, and COL22A1; (c) variants in previously reported genes, such 
as HMGA2, FGFR4, PTTG1, RB1, GNAS, AIP, and GPR101, were not detected by targeted resequencing; and 
(d) variants in BCHE, DARS, NGDN, and UNC5B were associated with increased biochemical activity of GH-
secreting pituitary tumors.
In GO analysis, only a small number of genes was related to GO terms, whereas enriched GO terms for 
previously reported genes showed significant overlaps with pituitary adenomas and acromegaly-related terms 
(p = 1.3 ×  10–60 and 1.6 ×  10–28, respectively). This indicates that previously reported genes are rarely observed in 
other disease categories, and that current variants found in this study do not overlap with those found previ-
ously. Although previous databases included mostly western populations, only East Asians were analyzed in 
this  study11,15,16. In several studies, ethnic differences were significantly associated with clinical manifestations 
and genetics of GH-secreting pituitary  adenoma17–19. Furthermore, we analyzed pure GH-secreting pituitary 
adenomas without GNAS variant rather than general sporadic cases. The difference in a subject’s ethnicity and 
inclusion criteria may be responsible for the differences in the GO results. Also, while this manuscript was 
being reviewed, the variants were searched again in the recently updated  COSMIC20 and  ClinVar21databases 
and most of the variants have not been reported or rarely observed and not reported as significantly pathogenic 
(Supplementary Table S7).
The underlying pathophysiology of pituitary tumorigenesis is characterized by a combination of disordered 
cell proliferation concomitant with dysregulated hormone hypersecretion. GH-secreting pituitary adenoma 
formation results in unrestrained somatotroph proliferation associated with intrinsic cell cycle dysfunction as 
well as activation of cAMP  signaling1. Most tumors are caused by heterogeneous variants, some of which are 
involved in the same molecular pathways and can promote tumor  development22. Although variants with high 
frequency or hotspots, such as GNAS, were not identified, variants in recurrent genes among 50 GH-secreting 
pituitary adenomas suggested that these variants are involved in GH production from somatotroph cells. Among 
the gene lists of targeted resequencing, variants in 14 genes were observed in at least two or more patients. 
Regarding kinase activity, MAST4, TNN, PLXND1, and COL22A1 are directly involved in the serine/threonine 
kinase family and PI3K-Akt and Akt signaling pathways, which can induce tumor formation in GH-secreting 
pituitary adenoma (www. genec ards. org)23–25. Furthermore, several mutated genes can be modulated by transcrip-
tion factors associated with GH-secreting pituitary adenomas. For example, PRIM2, DOCK4, and DARS can be 
modulated by STAT family proteins; COL22A1, NGDN, and UNC5b by GATA family proteins; and DNAH11 by 
aryl hydrocarbon receptor and translocator, which induce somatotroph tumor formation (www. genec ards. org).
GH secretion is controlled by  Ca2+ and adenosine ATP signaling, and both signals appear to be frequently 
activated in GH-secreting pituitary adenomas. Activated cAMP and  Ca2+ signaling lead to an increase in the 
cytosolic free calcium concentration in pituitary tumor  cells26,27. Moreover, ATP, which is simultaneously released 
with pituitary hormones, induces an increase in the intracellular free calcium concentration in pituitary  cells28. 
For example, Gsp variants induce constitutive activation of adenylate cyclase to convert ATP to cAMP. An 
increase in the intracellular cAMP concentration, in turn, leads to activation of protein kinase A and further 
mitogenic signaling in GH-secreting  cells8. From a clinical perspective, GNAS-mutated GH-secreting pitui-
tary adenomas present significantly increased biochemical activity among patients with acromegaly. Until now, 
genetic alterations associated with biochemical activity other than GNAS variants have not been reported. In 
this study, novel gene variants were identified in GH-secreting pituitary tumors and associated with biochemi-
cal activities. BCHE encodes butyryl cholinesterase and deacylate ghrelin, which stimulate GH secretion from 
 somatotrophs29, and DARS encodes aspartyl-tRNA synthetase and is modulated by CXC chemokine receptor 
(CXCR) 7 in somatotrophs. Several studies reported that the expression of CXCR7 is increased in prolactinoma, 
and that GH-secreting pituitary adenomas and CXCR7 reduce the activity of DARS30. NGDN encodes the E1F4E 
binding protein and, in leukemia cell lines, NGDN knockdown activates the mTOR  pathway31. UNC5B encodes a 
member of the netrin receptor family and is involved in angiogenesis. Furthermore, UNC5B was recently associ-
ated with aggressive behavior in null pituitary adenoma and silent subtype III pituitary corticotroph  adenomas32. 
However, there have been no reports on these genetic variants in GH-secreting pituitary adenoma.
This study had several limitations. Although variants in recurrent genes were identified, functional studies of 
all variants were not performed. Nevertheless, several variants in four genes influencing the biochemical activi-
ties of GH-secreting pituitary adenoma were introduced in GH3 cells, and functional studies were performed. 
Second, the frequency of variants was relatively lower than that of previously reported somatic variants, such 
as GNAS variants in GH-secreting pituitary adenomas and USP8 variants in Cushing’s disease. However, apart 
from GNAS, acromegaly-associated somatic variants are not well-established. Several studies have failed to 
demonstrate the clinical significance or recurrent variants of the reported somatic variants in sporadic GH-
secreting pituitary  tumors11,15,16. Furthermore, we found that variants actually promoted GH secretion in vitro 
in rat GH-secreting pituitary adenoma cells and human mutant vectors, showing high similarity between both 
human and rat sequences. Third, we excluded patients with GNAS variants and evaluated pure GH-expressing 
pituitary tumors in patients with acromegaly. In some conditions, GH-secreting pituitary adenomas are associ-
ated with somatic variants that combine with GNAS, except for hotspot variants; however, we sought to discover 
novel variants that function independently. Follow-up studies are needed to investigate the somatic variants 
found in this research. Finally, we did not evaluate granulation pattern of GH secreting pituitary tumors. Sev-
eral studies reported that sparsely granulated type is associated with mutations in the extracellular domain of 
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the growth hormone receptor and densely granulated type present more frequent GNAS  mutation33,34. Further 
studies evaluating genetic alterations according to granulation type would be necessary.
In conclusion, several somatic variants were identified in sporadic pure GH-secreting pituitary adenomas 
from patients who had neither GNAS variants nor a family history. Furthermore, GH-secreting pituitary tumors 
with variants in BCHE, DARS, NGDN, and UNC5B presented high biochemical activities including GH and 
IGF-1. Although no novel recurrent point variants were identified, the observed somatic variants may affect 
pathways involved in tumorigenesis and biochemical activities of GH-secreting pituitary adenomas. Further 
studies are needed to determine the functional mechanism of variants in selected genes that affect GH secretion 
and pituitary adenoma formation.
Methods
Patients. Among patients in the Severance Hospital Pituitary Tumor Cohort, 232 subjects received trans-
sphenoidal adenomectomy following a diagnosis of GH-secreting pituitary adenoma from January 2012 to Janu-
ary 2017 at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. All the enrolled patients 
were single ethnicity, Korean. GH-secreting pituitary tumors were confirmed by measuring serum insulin-like 
growth factor-1 (IGF-1) and nadir GH levels during the 75-g oral glucose tolerance test. Immunohistochemical 
staining of the operated pituitary tumors was performed for GH, prolactin, luteinizing hormone, follicle-stim-
ulating hormone, thyroid stimulating hormone, and adrenocorticotropic hormone. Pituitary tumors expressing 
hormones other than GH were excluded from this study. Finally, the tumor tissues of 140 patients with acro-
megaly expressing only GH were evaluated. No patients had a family history of pituitary adenoma. Pituitary 
tumors were classified based on dynamic magnetic resonance imaging of the sella turcica and parasellar region 
according to the modified Hardy radiological classifications, as described  previously35.
Immunoradiometric assay (hGH-RIACT; Cis Bio International, Gif-sur-Yvette, France) was used to measure 
the GH concentration. This assay had an analytical sensitivity of 0.03 μIU/mL, within-assay coefficient of varia-
tion (CV) of 1.3–2.1%, and inter-assay CV of 3.8–5.0%. The World Health Organization international standard 
(WHO IS 98/574) was used to classify GH values. An immunoradiometric assay system (IGF-1 NEXT IRMA CT; 
Biocode-Hycel, Liège, Belgium) was used to measure the IGF-1 concentration. The minimum detectable IGF-1 
concentration was 1.25 ng/L, within-assay CV was 2.6–4.4%, and inter-assay CV was 7.4–9.1%36.
This study was conducted in accordance with the Declaration of Helsinki and approved by our institutional 
review board and Ethics Committee (Yonsei University Institutional Review Board and Ethics Committee: 
approval # 4-2011-0740). Written informed consent was required and obtained from all patients.
WES. For WES, 29 patients agreed to tissue collection during transsphenoidal adenomectomy. Genomic 
DNA samples from fresh frozen tissue were extracted using a DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany). Variants at codons 201 and 227 in GNAS were tested by PCR followed by Sanger sequencing (Macro-
gen, Seoul, Korea). PCR and Sanger sequencing primers were designed to cover both hotspot variants of GNAS 
(Supplementary Table  S8). Eight GNAS variant-negative pituitary tumor samples and one additional sample 
prepared from FFPE tissue were subjected to WES, and each normal genomic DNA sample from blood was 
extracted using a DNeasy Blood & Tissue Kit (Qiagen). Shotgun DNA libraries for sequencing were constructed, 
and WES was performed (Celemics, Seoul, Korea) using the SureSelect Human All Exon V4 + UTRs kit (Agilent 
Technologies, Santa Clara, CA, USA). Each library was pooled and sequenced with a Hiseq2500 (Illumina, San 
Diego, CA, USA).
Analysis of exome data. Raw sequencing data (FASTQ) were aligned to the human genome (NCBI Build 
37; hg19) to generate a SAM format file using Novoalign (v. 2.07.18, Novocraft; http:// www. novoc raft. com/ 
produ cts/ novoa lign/). SAM files were converted to BAM format using SAMtools (v. 0.1.18, SAMtools; http:// 
www. htslib. org/)37, and each expanded data of tissue sample was merged into one BAM file. To modify the BAM 
files, duplications were removed using Picard v1.67 MarkDuplicates (Picard Tools; http:// broad insti tute. github. 
io/ picard/), and indels were fixed around a known indel position using built-in modules for indel realignment 
in Genome Analysis Tool Kit (GATK, v. 2.7.2, Broad Institute; https:// gatk. broad insti tute. org/ hc/ en- us)38. Base 
quality was recalibrated using modules for base quality recalibration in GATK.
Variants were called from modified BAM files using muTect (v. 1.1.4, Broad Institute; https:// softw are. broad 
insti tute. org/ cancer/ cga/ mutect)39 and Varscan2 (v. 2.2.11, http:// dkobo ldt. github. io/ varsc an/)40, annotated using 
Table_ANNOVAR with screening variants from several databases; Exome Sequencing Project 6500 (ESP6500), 
1000 Genome Project (1000GP), Cosmic, ClinVar, and functional prediction were filtered using PolyPhen-2 and 
avsift algorithms. We filtered variants with an allelic frequency > 1% in the database.
Targeted resequencing and data analysis. For single nucleotide variant (SNV) validation, probes were 
designed to cover 60 bp on either side of the targeted SNV, synthesized from microarray, and in vitro-transcribed 
to contain biotinylated UTP using a MAXIscript™ T7 Transcription Kit (Thermo Fisher Scientific, Waltham, 
MA, USA). Target regions were captured from tumor tissue samples used in exome sequencing, which was 
performed at Celemics, Inc.
Raw sequencing data (FASTQ) were aligned using Novoalign (v2.07.18). SAM files were converted to BAM 
format using SAMtools (v. 0.1.18). Each genotype of target loci was piled-up using the mpileup command in 
SAMtools and compared to exome sequencing data. Variants with a variant allele frequency > 0.1, total depth > 15, 
and variant depth > 2 were selected.
For target profiling, 120-bp probes were designed to cover the targeted region with 2 × tiling density (almost 
all probes half-overlapped with the nearest probe). The probes were prepared as described for the SNV validation 
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panel. Genomic DNA samples were extracted from FFPE samples using the QIAamp DNA FFPE Tissue Kit 
(Qiagen) and used to construct the NGS library with a SPARK™ DNA Sample Prep Kit (Enzymatics, Beverly, 
MA, USA); capture was performed at Celemics, Inc. Sequencing data were aligned and modified as described 
for exome sequencing analysis, and variants were called using the UnifiedGenotyper command in GATK.
Gene set enrichment analysis. GO was analyzed using the Enrichr tool (https:// amp. pharm. mssm. edu/ 
Enric hr/)41. A list of mutant genes was queried for four categories: “Rare Diseases GeneRIF Gene Lists,” “GO 
Biological Process2018,” “GO Cellular Component 2018,” and “GO Molecular Function 2018.” Enriched terms 
with a p-value < 0.05 were retrieved and ranked in ascending order.
Cell culture. GH3 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in high-
glucose Dulbecco’s modified Eagle’s medium (Hyclone, Logan, UT, USA) supplemented with 4 mM l-glutamine, 
10% fetal bovine serum (Hyclone), and penicillin–streptomycin solution (Hyclone) in a humidified atmosphere 
with 5%  CO2 and 95% air at 37 °C.
Transfection of mutant plasmids. pcDNA3.1-FLAG- BCHE, DARS, NGDN, or UNC5B wild-type (WT) 
was purchased from Origene (Rockville, MD, USA), and each mutant plasmid of target genes was generated with 
Site-Directed Mutagenesis Kits according to the manufacturer’s protocol (Thermo Fisher Scientific). To deter-
mine the effects of each variant on cancer cell properties, GH3 cells were transfected with pcDNA3.1 control 
vector, pcDNA3.1-FLAG-WT of target genes, or pcDNA3.1-FLAG-mutant of target genes using Polyjet reagent 
(Invitrogen, Carlsbad, CA, USA). The cells were analyzed by quantitative real-time polymerase chain reaction 
(qRT-PCR), western blotting, MTS assay (Promega, #G3582, Madison, WI, USA), and ELISA for GH (Merck, 
Kenilworth, NJ, USA) at 48 h after  transfection42.
qRT‑PCR. qRT-PCR was performed using a SYBR Green Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s protocols, using the following primers: rat Gh forward, 
5′-CAA AGA GTT CGA GCG TGC CTA-3′, and reverse, 5′-TGG GAT GGT CTC TGA GAA GCA-3′, rat Gapdh for-
ward, 5′- GGA TGG AAT TGT GAG GGA GA-3′, and reverse, 5′-GAG GAC CAG GTT GTC TCC TG-3′.
Western blot analysis. GH3 cells in 10-cm plates were lysed in radio-immunoprecipitation assay buffer 
(20 mM Tris, 2 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 5% phosphatase inhibitors, 0.5% protease inhibi-
tors), and the protein content was measured using a Coomassie (Bradford, UK) Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Equal amounts of protein (10 mg) were heat-denatured in 2 × sample buffer (2% SDS, 62.5 mM 
Tris, pH 6.8, 0.01% bromophenol blue, 1.43  mM mercaptoethanol, and 0.1% glycerol), separated on a 10% 
SDS–polyacrylamide gel, transferred onto polyvinylidene difluoride membranes (Bio-Rad), and blotted with 
the appropriate antibodies: anti-GH (Santa Cruz Biotechnology, Dallas, TX, USA), anti-tAKT (Cell Signaling 
Technology, Danvers, MA, USA), anti-pAKT (Cell Signaling Technology), anti-mTOR (Cell Signaling Technol-
ogy), anti-pCREB (Cell Signaling Technology), anti-tCREB (Cell Signaling Technology), and anti-β-actin (Santa 
Cruz Biotechnology). Immunocomplexes were detected using an enhanced chemiluminescence system (Cell 
Signaling Technology)43.
Statistical analysis. Continuous and categorical variables are expressed as the medians (range). The data 
were analyzed using the SPSS software package for Windows (v. 25.0, IBM; https:// www. ibm. com/ kr- ko/ analy 
tics/ spss- stati stics- softw are). The Mann–Whitney U test and Kruskal–Wallis test were used for continuous vari-
ables, and linear-by-linear association for categorical variables was performed as appropriate. All statistical tests 
were two-tailed, and a p-value < 0.05 was considered  significant36.
Data availability
All data generated or analyzed during this study are included in this published article or in the data repositories 
listed in References.
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